ESR1 and breast cancer: AKT2 knockdown inhibited the chemotaxis of breast cancer cells [31], whereas knockdown of AKT3 resulted in reduced expression of HER2 and HER3 and upregulation of ER-alpha, resulting in an increased responsiveness of murine model cells to antiestrogen [32].